Study on the Potential Mechanism of Fructus Tribuli in the Treatment of Hypertensive Vascular Remodeling Based on Network Pharmacology and Molecular Docking

Table 3

Topological parameters of the main targets of FT in the treatment of HVR.

Gene names	Protein names	Betweenness centrality	Closeness centrality	Degree
AKT1	RAC-alpha serine/threonine-protein kinase	0.07	0.75	111
MAPK3	Mitogen-activated protein kinase 3	0.06	0.75	108
VEGFA	Vascular endothelial growth factor A	0.06	0.73	106
SRC	Proto-oncogene tyrosine-protein kinase Src	0.04	0.73	102
IL6	Interleukin-6	0.05	0.71	99
EGFR	Epidermal growth factor receptor	0.04	0.70	94
MAPK1	Mitogen-activated protein kinase 1	0.03	0.70	93
TNF	Tumor necrosis factor	0.03	0.68	92
STAT3	Signal transducer and activator of transcription 3	0.02	0.68	88
MAPK8	Mitogen-activated protein kinase 8	0.01	0.64	75
MTOR	Serine/threonine-protein kinase mTOR	0.02	0.64	75
JUN	Transcription factor AP-1	0.01	0.64	74
HSP90AA1	Heat shock protein HSP 90-alpha	0.02	0.64	74
MMP9	Matrix metalloproteinase-9	0.01	0.62	69
MAPK14	Mitogen-activated protein kinase 14	0.01	0.62	68
PTGS2	Prostaglandin G/H synthase 2	0.01	0.62	68
CCND1	G1/S-specific cyclin-D1	0.01	0.62	67
ESR1	Estrogen receptor	0.01	0.61	64
ERBB2	Receptor tyrosine-protein kinase erbB-2	0.01	0.61	64
PIK3CA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	0.01	0.61	62
NOS3	Nitric oxide synthase, endothelial	0.02	0.62	62
FGF2	Fibroblast growth factor 2	0.01	0.60	59
PIK3R1	Phosphatidylinositol 3-kinase regulatory subunit alpha	0.01	0.59	55
PPARG	Peroxisome proliferator-activated receptor gamma	0.01	0.59	54
EP300	Histone acetyltransferase p300	0.01	0.59	54
STAT1	Signal transducer and activator of transcription 1-alpha/beta	0.01	0.59	53
APP	Amyloid-beta precursor protein	0.02	0.59	53
PRKCD	Protein kinase C delta type	0.01	0.56	44
NR3C1	Glucocorticoid receptor	0.02	0.57	43
F2	Prothrombin	0.01	0.56	41
PRKCA	Protein kinase C alpha type	0.01	0.56	41
HDAC1	Histone deacetylase 1	0.01	0.56	40
REN	Renin	0.01	0.56	38